{
    "organizations": [],
    "uuid": "bd505f3a342706e2e38167a43e15b5349732bedb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cellectar-granted-seminal-us-paten/brief-cellectar-granted-seminal-u-s-patent-for-phospholipid-ether-analogs-as-cancer-targeting-drug-vehicles-idUSFWN1R90JN",
    "ord_in_thread": 0,
    "title": "BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Cellectar Biosciences Inc:\n* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-27T20:08:00.000+03:00",
    "crawled": "2018-03-28T19:22:53.084+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "cellectar",
        "bioscience",
        "inc",
        "cellectar",
        "granted",
        "seminal",
        "patent",
        "analog",
        "drug",
        "vehicle",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}